Business Context and Reporting Period
This Form 8-K Current Report was filed by Kalaris Therapeutics, Inc. (KLRS) on April 4, 2025, covering events occurring on April 3, 2025. The Company is a Delaware corporation incorporated as an emerging growth company, with principal executive offices in Palo Alto, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Leone Patterson to the Board of Directors, effective immediately on April 3, 2025. Key details include:
- Board Election: Ms. Patterson was elected as a Class III director, with a term expiring at the 2026 annual meeting of stockholders.
- Committee Role: Ms. Patterson was elected as the Chair of the Audit Committee.
- Committee Composition: The Audit Committee now consists of Ms. Patterson (Chair), Anthony Adamis, M.D., and Morana Jovan-Embiricos, Ph.D.
- Compensation Program: The Company expects to adopt a new Non-Employee Director Compensation Program. Ms. Patterson will be eligible for compensation under this program once adopted.
- Indemnification: Ms. Patterson will enter into the Company's standard form of indemnification agreement, covering expenses such as attorneys' fees and judgments arising from her service.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The only noted contingency is the potential financial obligation under the indemnification agreement for Ms. Patterson, which may require the Company to cover certain legal expenses and settlements. There are no reported family relationships or undisclosed transactions between Ms. Patterson and the Company.
Investor Verification Checklist
- Verify the adoption timeline and specific terms of the new Non-Employee Director Compensation Program.
- Review the standard form of indemnification agreement filed as Exhibit 10.6 to the March 18, 2025, Form 8-K.
- Confirm the background and qualifications of the new Audit Committee Chair, Leone Patterson.
- Monitor future filings for the formal adoption of the director compensation plan.